Medline stock is a little too expensive to buy post IPO, Jim Cramer says
CNBC's Jim Cramer reviewed Medline, a medical supplies giant that made its market debut Wednesday.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.